Tom Snelling
Overview
Explore the profile of Tom Snelling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahar R, McGlothlin A, Dymock M, Barina L, Bonten M, Bowen A, et al.
Trials
. 2025 Feb;
26(1):49.
PMID: 39934879
Platform trials have become widely adopted across multiple disease areas over recent years, however, guidelines for operationalising these trials have not kept pace. We outline a series of documents that...
2.
Walker H, McLeman L, Meyran D, Goh L, Summers P, Stopler J, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39921207
An adaptive platform trial (APT) offers the ability to incorporate several research questions in the same target population across multiple domains (interventions), with the ability to add new questions in...
3.
Snelling T, Garnotel L, Jeru I, Tusseau M, Cuisset L, Perlat A, et al.
Open Biol
. 2024 Dec;
14(12):240260.
PMID: 39626775
Retinal dystrophy, optic nerve oedema, splenomegaly, anhidrosis and migraine headache (ROSAH) syndrome is an autosomal dominant disorder and to date is known to be caused by either the Thr237Met or...
4.
Snelling T
Bio Protoc
. 2024 Nov;
14(22):e5113.
PMID: 39600975
Alpha-protein kinase 1 (ALPK1) is normally activated by bacterial ADP-heptose as part of the innate immune response, leading to the initiation of downstream signalling events that culminate in the activation...
5.
Snelling T
Bio Protoc
. 2024 Nov;
14(22):e5124.
PMID: 39600973
ALPK1 is an atypical protein kinase that is activated during bacterial infection by ADP-heptose and phosphorylates TIFA to activate a cell signaling pathway. In contrast, specific mutations in ALPK1 allow...
6.
Cohen P, Snelling T
Trends Biochem Sci
. 2024 Nov;
50(1):61-70.
PMID: 39580356
Protein kinases regulate many intracellular processes, and their dysregulation causes cancers and other diseases. This review focuses on the atypical alpha-kinase 1 (ALPK1), which is activated in mammalian cells by...
7.
Reynolds R, Tay E, Dymock M, Deng L, Glover C, Lopez L, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340003
Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses...
8.
Dymock M, McLeod C, Richmond P, Snelling T, Marsh J
Trials
. 2024 Jul;
25(1):507.
PMID: 39060943
The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies...
9.
Griffin D, Dymock M, Wong G, Morrissey C, Lewin S, Cheng A, et al.
Trials
. 2024 Jul;
25(1):485.
PMID: 39020446
Background: Immunocompromised hosts (ICH) experience more breakthrough infections and worse clinical outcomes following infection with COVID-19 than immunocompetent people. Prophylactic monoclonal antibody therapies can be challenging to access, and escape...
10.
Perez Chacon G, Estcourt M, Totterdell J, Marsh J, Perrett K, Campbell D, et al.
PLoS Med
. 2024 Jun;
21(6):e1004414.
PMID: 38857311
Background: In many countries, infant vaccination with acellular pertussis (aP) vaccines has replaced use of more reactogenic whole-cell pertussis (wP) vaccines. Based on immunological and epidemiological evidence, we hypothesised that...